Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662411 | 0.87 | GRIN2B (0.76) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL3760581 | 0.83 | TAAR1 (0.75) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL3907332 | 0.83 | TAAR1 (0.81) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL24075499 | 0.81 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL22216853 | 0.81 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL3665298 | 0.81 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL24767088 | 0.81 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL25002632 | 0.81 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL21792273 | 0.81 | TAAR1 (0.84) | GRIN2BTAAR1SIGMAR1GRIN1OPRL1 | |
| SCHEMBL375264 | 0.81 | GRIN2B (0.62) | GRIN2BOPRL1OPRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| EP-1636224-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | Prosidion Limited (GB) | 2006-03-22 | — | — | EP | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| EP-1247807-B1 | PROCESSES FOR PRODUCING TETRAHYDROPYRANYL-4-SULFONATE AND 4-AMINOTETRAHYDROPYRAN COMPOUND | UBE INDUSTRIES (JP) | 2004-04-28 | — | — | EP | disclosed |
| US-6653489-B2 | Reacting 3-buten-1-ol with a formaldehyde compound and an organic sulfonic acid | UBE INDUSTRIES, INC. (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030004359-A1 | Processes for producing tetrahydropyranyl-4-sulfonates and 4-aminotetrahydropyran compound | UBE INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1247807-A1 | PROCESSES FOR PRODUCING TETRAHYDROPYRANYL-4-SULFONATE AND 4-AMINOTETRAHYDROPYRAN COMPOUND | Ube Industries, Ltd. (JP) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004359-A1 | Processes for producing tetrahydropyranyl-4-sulfonates and 4-aminotetrahydropyran compound | HPD, DHPS, FDPS | GRIN2B 4145/4885TAAR1 2241/4885SIGMAR1 2204/4885 |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | GRIN2B 2477/4885TAAR1 4634/4885SIGMAR1 4002/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | GRIN2B 2477/4885TAAR1 4634/4885SIGMAR1 4002/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | GRIN2B 2477/4885TAAR1 4634/4885SIGMAR1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.